Bank of America Downgrades Novavax to Underperform Citing Long-Term Growth Concerns
Bank of America downgraded Novavax to Underperform due to concerns about the vaccine maker's sustainable growth prospects amid shifting COVID-19 variants and heightened FDA regulatory requirements.
